Droxidopa

Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) [1][2][3][4].

Product Specifications

CAS Number

[23651-95-8]

Product Name Alternative

L-DOPS; DOPS; SM5688

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/droxidopa.html

Purity

98.80

Solubility

DMSO : 21.74 mg/mL (ultrasonic; warming; adjust pH to 3 with 1 M HCl; heat to 60°C)

Smiles

OC1=C(O)C=CC([C@@H](O)[C@@H](C(O)=O)N)=C1

Molecular Formula

C9H11NO5

Molecular Weight

213.19

Precautions

H315, H319, H335

References & Citations

[1]Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83 (4) .|[2]Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826.|[3]Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016;2016:6383240. |[4]Kaufmann H. L-dihydroxyphenylserine (Droxidopa) : a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.